Estuardo Aguilar-Cordova - Jul 29, 2021 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Chief Scientific Officer, Director
Signature
/s/ John Canepa, Attorney-in-Fact
Stock symbol
CADL
Transactions as of
Jul 29, 2021
Transactions value $
$0
Form type
4
Date filed
8/2/2021, 08:12 PM
Previous filing
Jul 26, 2021
Next filing
May 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CADL Common Stock Conversion of derivative security +162K +18.99% 1.02M Jul 29, 2021 Direct F1, F2
holding CADL Common Stock 2.07M Jul 29, 2021 By Estuardo Aguilar-Cordova 2020 Irrevocable Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CADL Series B Preferred Stock Conversion of derivative security $0 -399K -100% $0.00* 0 Jul 29, 2021 Common Stock 162K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.
F2 Includes 32,399 shares of common stock held jointly with spouse.
F3 Shares held by the Estuardo Aguilar-Cordova 2020 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

Remarks:

Exhibit 24 - Power of Attorney